Challenges of Targeting Cytokines in MS: Stephanie Blandford, MSc
March 21st 2021The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed the potential of interleukin-1 receptor antagonist as a biomarker in MS disability as well as a therapeutic target.
COVID-19 and Muscular Dystrophies, and R&D for Rare Disorders: Sharon Hesterlee, PhD
March 16th 2021The executive vice president and chief research officer of the MDA offered her perspective on the ongoing conversations about and impact of the pandemic on the care of patients with muscular dystrophies.